Hypothesis: A minimal glycan shield with specific sugar composition on the envelope glycoprotein (Env) of HIV- 1 may be necessary for establishing new infections. In the HIV ?selected? for a new infection, glycan content/composition on Env could differ based on the mode and receptacle of transmission (e.g. rectal, penile, foreskin, vaginal, and cervical tissue in sexual transmission) as well as the cytokine/chemokine milieu and microbiome. Understanding glycan composition on the transmitted HIV-1 in these microenvironments would improve the design and effectiveness of humoral-based HIV-1 vaccine. For the past 15 years, this R01 has compared HIV disease parameters to replicative HIV fitness in T cells, macrophages, dendritic cell cocultures, and various ex vivo, non-mucosal tissues. We have shown that competitive replicative fitness of patient-derived HIV is a surrogate of pathogenesis and in the absence of treatment, was a strong correlate of disease progression. However, our published work indicates that ?pathogenic? and ?transmission? fitness of primary HIV-1 isolates are quite distinct. Using varying conditions with human explant penile and endocervical (EnC) tissues exposed to over 20 different mixtures of HIV-1 derived from acute and chronic disease, we now have a clearer picture of factors impacting HIV transmission. We observed ?trapped? replication of chronic HIV-1 in mucosal (penile and cervical) tissue while the acute HIV-1 isolates were carried through the tissue (possibly via DCs) to infect Th17 or Th1 CD4+ T cells. HIV-1 that ?escapes? mucosal tissues typically have lower affinity for C type lectins and fewer N linked glycosylation sites. To enhance these studies we worked closely with programmers and bioinformatic specialists to develop robust NGS analysis pipelines to determine transmission fitness from multivirus competitions and more recently, we optimized EIS-MS techniques to analyze gp120 glycans. We have proposed four highly inter-related aims to test our hypotheses:
Specific Aim 1. In vivo analyses of HIV-1 in endocervical (EnC) and plasma samples and determinants of new HIV transmissions. Examine Env sequence features in the EnC and blood of newly infected women as well as in women with HIV-1 infection in the EnC but who have not seroconverted.
Specific Aim 2. Characterizing the properties of transmitted/founder (TF) HIV variant in blood versus the transmitted HIV-1 population in the female and male genital tract: Ex vivo study. Measure trapped replication in the tissue versus transmission in human penile, foreskin, cervical, and vaginal explant model.
Specific Aim 3. To measure lectin binding affinity and to analyze the glycosylation pattern on the gp120 Env of highly transmissible TF HIV-1 using new gp120 purification techniques and EIS-MS.
Specific Aim 4. To modify the glycans on TF and EnC viruses and to determine optimal HIV Env for male to female HIV transmissions using the same methods described in aims 2 and 3.

Public Health Relevance

Rapid evolution of HIV within an infected individual leads to immune escape and has been hallmark feature of this slow progressing disease. Although each new infection in women is typically established by a single HIV clone, we recently discovered that the female genital tract is infected by diverse HIV-1 population and that the severe genetic bottleneck at transmission may occur from the vaginal tract to the blood. In this grant proposal, we will define the specific sugars on the HIV-1 coat that can break the sugar-binding vaginal trap and lead to systemic infection in the hopes of defining a specific viral attribute to target with various prevention strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI049170-14A1
Application #
10025713
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Refsland, Eric William
Project Start
2002-09-27
Project End
2025-04-30
Budget Start
2020-05-11
Budget End
2021-04-30
Support Year
14
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Western Ontario
Department
Type
DUNS #
208469452
City
London
State
ON
Country
Canada
Zip Code
N6 3K7
Pankrac, Joshua; Klein, Katja; McKay, Paul F et al. (2018) A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. NPJ Vaccines 3:2
Klein, Katja; Nickel, Gabrielle; Nankya, Immaculate et al. (2018) Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection. PLoS Pathog 14:e1006754
Bagaya, Bernard S; Tian, Meijuan; Nickel, Gabrielle C et al. (2017) An in vitro Model to Mimic Selection of Replication-Competent HIV-1 Intersubtype Recombination in Dual or Superinfected Patients. J Mol Biol 429:2246-2264
Gibson, Richard M; Nickel, Gabrielle; Crawford, Michael et al. (2017) Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries. Infect Dis Poverty 6:163
Krebs, Kendall C; Tian, Meijuan; Asmal, Mohammed et al. (2016) Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections. AIDS Res Ther 13:41
Venner, Colin M; Nankya, Immaculate; Kyeyune, Fred et al. (2016) Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa. EBioMedicine 13:305-314
Kyeyune, Fred; Gibson, Richard M; Nankya, Immaculate et al. (2016) Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure. Antimicrob Agents Chemother 60:3380-97
Asmal, Mohammed; Lane, Sophie; Tian, Meijuan et al. (2016) Pathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from CCR5-using envelope genes of acute HIV-1 infections. Virology 499:298-312
Choi, Eunsil; Michalski, Chad J; Choo, Seung Ho et al. (2016) First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses. Retrovirology 13:82
Tebit, Denis M; Patel, Hamish; Ratcliff, Annette et al. (2016) HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs. AIDS Res Hum Retroviruses 32:676-88

Showing the most recent 10 out of 44 publications